as 12-18-2024 3:37pm EST
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Founded: | 1986 | Country: | United States |
Employees: | N/A | City: | CRANBURY |
Market Cap: | 25.4M | IPO Year: | 1993 |
Target Price: | $17.00 | AVG Volume (30 days): | 365.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.95 | EPS Growth: | N/A |
52 Week Low/High: | $0.68 - $5.65 | Next Earning Date: | 02-13-2025 |
Revenue: | $2,384,113 | Revenue Growth: | -60.85% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
PTN Breaking Stock News: Dive into PTN Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
PR Newswire
2 days ago
PR Newswire
23 days ago
Thomson Reuters StreetEvents
a month ago
GuruFocus.com
a month ago
PR Newswire
a month ago
PR Newswire
a month ago
PR Newswire
a month ago
The information presented on this page, "PTN Palatin Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.